Halozyme Therapeutics (HALO) Retained Earnings (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Retained Earnings data on file, last reported at -$12.7 million in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$12.7 million, down 102.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.7 million (down 102.66% YoY), and the FY2025 annual result was $54.8 million, down 84.78% from the prior year.
• Retained Earnings fell to -$12.7 million in Q1 2026 per HALO's latest filing, from $54.8 million in the prior quarter.
• Over five years, Retained Earnings peaked at $502.1 million in Q3 2025 and troughed at -$12.7 million in Q1 2026.
• A 5-year average of $133.3 million and a median of $54.8 million in 2025 frame the typical range for Retained Earnings.
• On a YoY basis, Retained Earnings climbed as much as 610921.43% in 2022 and fell as far as 30911.11% in 2022.
• A 5-year view of Retained Earnings shows it stood at -$922000.0 in 2022, then soared by 9921.04% to $90.6 million in 2023, then jumped by 297.43% to $359.9 million in 2024, then plunged by 84.78% to $54.8 million in 2025, then tumbled by 123.19% to -$12.7 million in 2026.
• Business Quant data shows HALO's Retained Earnings at -$12.7 million in Q1 2026, $54.8 million in Q4 2025, and $502.1 million in Q3 2025.